The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

The inhaler is not reusable. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in rapidly deteriorating or potentially life-threatening ...

These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Salmeterol is a selective LABA. The pharmacologic effects of beta 2-adrenoceptor agonist drugs ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...

Current controller drugs for asthma include ICS, LABA, LTRA, omalizumab and theophylline. Current rescue drugs for asthma include short-acting β 2 agonists (SABA), short-acting muscarinic ...